New search Hide text from Guidelines
H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINSThis group comprises all hormonal preparations for systemic use, except:
- Insulins, see A10.
- Anabolic steroids, see A14.
- Catecholamines, see C01C and R03C.
- Sex hormones, see G03.
- Sex hormones used in treatment of neoplastic diseases, see L02.
- Metreleptin used for treatment of complications of leptin deficiency in patients with generalised lipodystrophy is classified in A16AA.
| The DDDs are generally based on the treatment or diagnosis of endocrine disorders. |
H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
H01C HYPOTHALAMIC HORMONES
This group comprises hypothalamic hormones; extracts, purified natural hormones and synthetic analogues.
Hypothalamic hormones used as diagnostic agents for pituitary function are classified in V04CD.
H01CA Gonadotropin-releasing hormones
Buserelin, goserelin, histrelin, leuprorelin, and triptorelin are classified in L02AE Gonadotropin releasing hormone analogues.
Gonadorelin used as diagnostic agent is classified in V04CM.
| The DDD of nafarelin is based on the treatment of endometriosis. No other DDDs have been assigned, due to the highly variable dosages used. |
H01CB Somatostatin and analogues
Somatostatin, octreotide and lanreotide, which are also used in cancer, are classified in this group.
| The DDDs of octreotide and lanreotide are based on the treatment of acromegaly. |
H01CC Anti-gonadotropin-releasing hormones
Last updated: 2024-01-26